Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study

Lancet

Volumn 363, Issue 9417, 2004, Pages 1253-1263

  Van Leth, F ^a   Phanuphak, P ^b   Ruxrungtham, K ^b   Baraldi, E ^c   Miller, S ^d   Gazzard, B ^e   Cahn, P ^f   Lalloo, U G ^g   Van Der Westhuizen, I P ^c   Malan, D R ^c   Johnson, M A ^h   Santos, B R ⁱ   Mulcahy, F ^j   Wood, R ^k   Levi, G C ^l   Reboredo, G ^m   Squires, K ⁿ   Cassetti, I ^o   Petit, D ^p   Raffi, F ^q   Katlama, C ^r   Murphy, R L ^s   Horban, A ^t   Dam, J P ^a   Hassink, E ^a   Van Leeuwen, R ^a   Robinson, P ^u   Wit, F W ^a   Lange, J M A ^a   more..

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c Embassy Drive Medical Center ^*  (United Kingdom)

^d Innovir Institute   (United Kingdom)

^e CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^f FUNDACIÓN HUÉSPED   (Argentina)

^g UNIVERSITY OF KWAZULU NATAL   (South Africa)

^h ROYAL FREE HOSPITAL   (United Kingdom)

ⁱ HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

^j ST JAMES S HOSPITAL   (Ireland)

^k UNIVERSITY OF CAPE TOWN   (South Africa)

^l INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS   (Brazil)

^m HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

ⁿ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^o Fundacion Centro de Estudios Infectologicos   (Argentina)

^p Listowell RD Woodstock   (South Africa)

^q NANTES UNIVERSITY HOSPITAL   (France)

^r PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^s NORTHWESTERN UNIVERSITY   (United States)

^t Wojewodzki Szpital Zakazny   (Poland)

^u BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; VIRUS RNA;

ADULT; ANXIETY; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE COURSE; FEMALE; FEVER; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTICENTER STUDY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; TREATMENT FAILURE; UNPLEASANT DREAM; VOMITING;

EID: 11144357656     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)15997-7     Document Type: Article

References (35)

1. Staszewski S., Morales-Ramirez J., Tashima K.T., et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults: Study 006 Team. N Engl J Med. 341:1999;1865-1873.
2. Van Leeuwen R., Katlama C., Murphy R.L., et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS. 17:2003;987-999.
3. Podzamczer D., Ferrer E., Consiglio E., et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir Ther. 7:2002;81-90.
4. Mannheimer S., Friedland G., Matts J., Child C., Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 34:2002;1115-1121.
5. Garcia de Olalla P., Knobel H., Cgroupona A., Guelar A., Lopez-Colomes J.L., Cayla J.A. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 30:2002;105-110.
6. Flandre P., Peytavin G., Meiffredy V., et al. Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial. Antivir Ther. 7:2002;113-121.
7. Cozzi-Lepri A., Phillips A.N., d'Arminio Monforte A., et al. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals study. J Infect Dis. 185:2002;1062-1069.
8. Keiser P., Nassar N., White C., Koen G., Moreno S. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naive patients: a cohort study. HIV Clin Trials. 3:2002;296-303.
9. Matthews G.V., Sabin C.A., Mandalia S., et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS. 16:2002;53-61.
10. Kollmann C., Tremblay C., Giguel F., Chou T.C., Hirsch M.S. In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz. Antivir Ther. 6:2001;143-144.
11. King R.W., Klabe R.M., Reid C.D., Erickson-Viitanen S.K. Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors. Antimicrob Agents Chemother. 46:2002;1640-1646.
12. Veldkamp A.I., Harris M., Montaner J.S., et al. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. J Infect Dis. 184:2001;37-42.
13. Veldkamp A.I., Weverling G.J., Lange J.M., et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS. 15:2001;1089-1095.
14. AIDS Clinical Trial Group. Table of grading severity of adult adverse experiences. 1996;Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville MD.
15. Anon H. revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992. 41:1993;1-19.
16. Albrecht M.A., Bosch R.J., Hammer S.M., et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med. 345:2001;398-407.
17. Friedl A.C., Ledergerber B., Flepp M., et al. Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. AIDS. 15:2001;1793-1800.
18. Garcia F., Knobel H., Sambeat M.A., et al. Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study. AIDS. 14:2000;2485-2494.
19. Raffi F., Reliquet V., Ferre V., et al. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults. Antivir Ther. 5:2000;267-272.
20. Raboud J.M., Rae S., Vella S., et al. Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. J Acquir Immune Defic Syndr. 22:1999;260-266.
21. Gazzard B., Moyle G. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet. 352:1998;314-316.
22. Núñez M., Soriano V., Martin-Carbonero L., et al. SENC (Spanish efavirenz vs nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals. HIV Clin Trials. 3:2002;186-194.
23. Kitahata M.M., Van Rompaey S.E., Shields A.W. Physician experience in the care of HIV-infected persons is associated with earlier adoption of new antiretroviral therapy. J Acquir Immune Defic Syndr. 24:2000;106-114.
24. Phillips A.N., Grabar S., Tassie J.M., Costagliola D., Lundgren J.D., Egger M. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. AIDS. 13:1999;2075-2082.
25. Roujeau J.C., Stern R.S. Severe adverse cutaneous reactions to drugs. N Engl J Med. 331:1994;1272-1285.
26. Dolan P.A., Flowers F.P., Araujo O.E., Sheretz E.F. Toxic epidermal necrolysis. J Emerg Med. 7:1989;65-69.
27. Schiodt F.V., Lee W.M. Fulminant liver disease. Clin Liver Dis. 7:2003;331-349.
28. Bissell D.M., Gores G.J., Laskin D.L., Hoofnagle J.H. Drug-induced liver injury: mechanisms and test systems. Hepatology. 33:2001;1009-1013.
29. Montaner J.S., Reiss P., Cooper D., et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. JAMA. 279:1998;930-937.
30. Pollard R.B., Robinson P., Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther. 20:1998;1071-1092.
31. van Heeswijk R.P., Veldkamp A.I., Mulder J.W., et al. The steady- state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS. 14:2000;F77-82.
32. Havlir D., Cheeseman S.H., McLaughlin M., et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis. 171:1995;537-545.
33. Sulkowski M.S., Thomas D.L., Mehta S.H., Chaisson R.E., Moore R.D. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 35:2002;182-189.
34. den Brinker M., Wit F.W., Wertheim-van Dillen P.M., et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 14:2000;2895-2902.
35. Matthews G, Mandalia S, Orkin C, et al. Durability of efavirenz compared to nevirapine with long term follow-up of an antiretroviral naive cohort. 9th Annual Conference of the British HIV Association, Manchester, UK: April 24-26, 2003.